Some new quinazolin-4(3H)-one derivatives, synthesis and antitumor activity

被引：26
作者：
Alafeefy, Ahmed Mahmoud [1 ]
机构：
[1] Al Kharj Univ, Dept Pharmaceut Chem, Coll Pharm, Al Kharj, Saudi Arabia
来源：
JOURNAL OF SAUDI CHEMICAL SOCIETY | 2011年 / 15卷 / 04期
关键词：
Anticancer; Cytotoxicity; Quinazoline; Synthesis; TYROSINE KINASE INHIBITORS; IRREVERSIBLE INHIBITORS; CYTOTOXICITY; QUINAZOLINE; GEFITINIB; BINDING; DESIGN; POTENT; FAMILY;
D O I：
10.1016/j.jscs.2011.06.019
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
A series of some new 2,3-disubstituted-6-iodo-3H-quinazolin-4-one derivatives was prepared and screened for their in vitro antitumor activity against the human breast cancer cell line (MCF-7), human cervix carcinoma cell line (HeLa), human liver cancer cell line (HepG2) and human colon cancer cell line HCT-8. Five compounds exhibited broad spectrum antitumor activity, better than the standard drug Doxorubicin (CAS-23214-92-8) against the four tested cell lines. In the present study, MCF-7 cell line was the most sensitive one, 12 compounds were good cytotoxic towards it. The best cytotoxic results were obtained with compounds bearing allyl and/or benzyl moiety at positions 2 and/or 3 of the quinazoline nucleus. (C) 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.
引用
收藏
页码：337 / 343
页数：7
相关论文
共 19 条
[1]   Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c] isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity [J].
Antony, Smitha ;
Agama, Keli K. ;
Miao, Ze-Hong ;
Hollingshead, Melinda ;
Holbeck, Susan L. ;
Wright, Mollie H. ;
Varticovski, Lyuba ;
Nagarajan, Muthukaman ;
Morrell, Andrew ;
Cushman, Mark ;
Pommier, Yves .
MOLECULAR PHARMACOLOGY, 2006, 70 (03) :1109-1120
[2]   The 4-anilinoquinazoline class of inhibitors of the erb B family of receptor tyrosine kinases [J].
Denny, WA .
FARMACO, 2001, 56 (1-2) :51-56
[3]   Design, Synthesis, and DNA-Binding of N-Alkyl(anilino)quinazoline Derivatives [J].
Garofalo, Antonio ;
Goossens, Laurence ;
Baldeyrou, Brigitte ;
Lemoine, Amelie ;
Ravez, Severine ;
Six, Perrine ;
David-Cordonnier, Marie-Helene ;
Bonte, Jean-Paul ;
Depreux, Patrick ;
Lansiaux, Amelie ;
Goossens, Jean-Francois .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (22) :8089-8103
[4]   Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence [J].
Gridelli, C. ;
De Marinis, F. ;
Di Maio, M. ;
Cortinovis, D. ;
Cappuzzo, F. ;
Mok, T. .
LUNG CANCER, 2011, 71 (03) :249-257
[5]  
JERRY WS, 2006, NAT REV DRUG DISCOV, P577
[6]   miR-145, miR-133a and miR-133b: tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma [J].
Kano, Masayuki ;
Seki, Naohiko ;
Kikkawa, Naoko ;
Fujimura, Lisa ;
Hoshino, Isamu ;
Akutsu, Yasunori ;
Chiyomaru, Takeshi ;
Enokida, Hideki ;
Nakagawa, Masayuki ;
Matsubara, Hisahiro .
INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (12) :2804-2814
[7]   Tyrosine kinase inhibitors.: 19.: 6-alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors [J].
Klutchko, SR ;
Zhou, HR ;
Winters, RT ;
Tran, TP ;
Bridges, AJ ;
Althaus, IW ;
Amato, DM ;
Elliott, WL ;
Ellis, PA ;
Meade, MA ;
Roberts, BJ ;
Fry, DW ;
Gonzales, AJ ;
Harvey, PJ ;
Nelson, JM ;
Sherwood, V ;
Han, HK ;
Pace, G ;
Smaill, JB ;
Denny, WA ;
Showalter, HDH .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (04) :1475-1485
[8]  
KOTTKE K, 1977, PHARMAZIE, V32, P540
[9]   Taking Quinazoline as a General Support-Nog to Design Potent and Selective Kinase Inhibitors: Application to FMS-like Tyrosine Kinase 3 [J].
Li, Wei-Wei ;
Chen, Jin-Juan ;
Zheng, Ren-Lin ;
Zhang, Wen-Qin ;
Cao, Zhi-Xing ;
Yang, Ling-Ling ;
Qing, Xiao-Yu ;
Zhou, Liang-Xue ;
Yang, Li ;
Yu, Luo-Ding ;
Chen, Li-Juan ;
Wei, Yu-Quan ;
Yang, Sheng-Yong .
CHEMMEDCHEM, 2010, 5 (04) :513-516
[10]  
Lin HQ, 2010, ANTICANCER RES, V30, P4899
12